L-3'-F2CCG-I

Discontinued Product

L-3'-F2CCG-I (Cat. No. 1058) has been withdrawn from sale for commercial reasons.
Description: Potent group I/group II agonist
Chemical Name: (2S,1'S,2'S)-2-(2'-Carboxy-3',3'-difluorocyclopropyl)glycine
Datasheet
Citations
Reviews
Literature (5)

Biological Activity for L-3'-F2CCG-I

Metabotropic glutamate receptor agonist, exhibits "priming" effect on the monosynaptic reflex.

Licensing Information

Sold with the permission of Nippon Chemiphar Co Ltd.

Technical Data for L-3'-F2CCG-I

M. Wt 195.12
Formula C6H7F2NO4
Storage Desiccate at +4°C
Smiles [H][C@@]1([C@](O)=O)[C@]([C@]([H])(N)C(O)=O)([H])[C@](F)1F

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for L-3'-F2CCG-I

Certificate of Analysis / Product Datasheet
Select another batch:

References for L-3'-F2CCG-I

References are publications that support the biological activity of the product.

Ishida and Shinozaki (1999) Inhibition of uptake and release of a novel mGluR agonist (L-F2CCG-I) by anion transport blockers in the rat spinal cord. Neuropharmacology 38 1531 PMID: 10530815

Saitoh et al (1998) Potentiation by DL-α-aminopimelate of a novel mGluR agonist (L-F2CCG-I) on the monosynaptic excitation in the rat spinal cord. Br.J.Pharmacol. 123 771 PMID: 9517398

Shinozaki et al (1996) Pharmacological activities of fluoride CCG derivatives: discovery of a novel agonist for metabotropic glutamate receptors. Soc.Neurosci.Abstr. 22 412.3

View Related Products by Product Action

View all Glutamate (Metabotropic) Group I Receptor Agonists

Keywords: L-3'-F2CCG-I, L-3'-F2CCG-I supplier, Potent, group, I, II, agonists, mGlur, Group, Receptors, mGlu1, mGlu5, mGluR1, mGluR5, Glutamate, Metabotropic, mGlu2, mGlu3, mGluR2, mGluR3, L-3-F2CCG-I, (Metabotropic), 1058, Tocris Bioscience

Citations for L-3'-F2CCG-I

Citations are publications that use Tocris products.

Currently there are no citations for L-3'-F2CCG-I.

Reviews for L-3'-F2CCG-I

There are currently no reviews for this product. Be the first to review L-3'-F2CCG-I and earn rewards!

Have you used L-3'-F2CCG-I?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.